| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Paid-in-kind interest on long-term debt | NaN | 107 | 4,580 | 4,406 |
| Net loss | -25,196 | 61,831 | -31,333 | -53,180 |
| Non-cash loss on extinguishment of debt and exchange transaction | NaN | 0 | 0 | 0 |
| Non-cash royalty revenue | 18,481 | 14,635 | 16,359 | 24,061 |
| Depreciation expense | 27 | 26 | 26 | 53 |
| Accretion and amortization of premiums and discounts on investments | NaN | 0 | NaN | NaN |
| Amortization of debt issuance costs and discounts | 589 | 641 | 847 | 1,519 |
| Non-cash interest expense related to the revenue interest liability | NaN | 0 | 0 | 0 |
| Non-cash interest expense related to the royalty sale liability | 13,894 | 16,211 | 14,637 | 26,363 |
| Deferred revenue | NaN | 3,798 | 8,366 | 13,795 |
| Stock-based compensation expense | 2,502 | 2,387 | 2,349 | 5,134 |
| Accounts receivable | -7,838 | 21,210 | 11,234 | 27,604 |
| Prepaids and other assets | 17,338 | 8,906 | 6,176 | 15,718 |
| Inventories | -915 | -3,415 | -5,927 | 19,975 |
| Other long-term liabilities | NaN | 1,303 | 0 | 7,436 |
| Deferred revenue | 9,054 | NaN | NaN | NaN |
| Accounts payable | 3,338 | -12,445 | 2,901 | 30,462 |
| Other accrued liabilities | -4,864 | 12,720 | 21,183 | -2,680 |
| Net cash used in operating activities | -27,722 | 45,243 | -4,286 | -54,050 |
| Proceeds from sales/maturities of investments | NaN | 0 | NaN | NaN |
| Purchase of property and equipment | 189 | 0 | 0 | 0 |
| Net cash used in investing activities | -189 | 0 | 0 | 0 |
| Proceeds from royalty sale liability | NaN | 0 | 0 | 0 |
| Payment of royalty sale liability issuance costs | NaN | 0 | 0 | NaN |
| Repurchase or principal payment of revenue interest liability | NaN | 0 | 0 | 0 |
| Payments on revenue interest liability | NaN | 0 | 0 | 0 |
| Proceeds from credit agreement, net of issuance costs | NaN | 0 | NaN | NaN |
| Proceeds from issuance of convertible notes, net of issuance costs | NaN | 0 | NaN | NaN |
| Proceeds from exercise of common stock options | NaN | NaN | 141 | 0 |
| Repayment of convertible notes | NaN | 54,912 | NaN | NaN |
| Proceeds from issuance of common stock, net of issuance costs | NaN | 72,596 | 0 | 0 |
| Proceeds from issuance of common stock from atm program, net of issuance costs | NaN | 2,027 | 10,531 | 2,850 |
| Proceeds from exercise of warrants, net of issuance costs | 16,217 | 10,348 | 0 | 0 |
| Payment of issuance costs | 0 | 0 | 0 | 7,500 |
| Other financing activities | NaN | 244 | NaN | NaN |
| Net cash provided by (used in) financing activities | 16,217 | 30,162 | 10,672 | -4,650 |
| Net decrease in cash and cash equivalents | -11,694 | 75,405 | 6,386 | -58,700 |
| Cash and cash equivalents at beginning of period | 167,852 | 92,447 | 144,761 | NaN |
| Cash and cash equivalents at end of period | 156,158 | 167,852 | 92,447 | NaN |
Esperion Therapeutics, Inc. (ESPR)
Esperion Therapeutics, Inc. (ESPR)